in the absence of a submission from the holder of the marketing authorisation:
sebelipase alfa (Kanuma®) is not recommended for use within NHSScotland.
Indication under review: Long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice621KB (PDF)
- Medicine name:
- sebelipase alfa (Kanuma)
- SMC ID:
Long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
- Pharmaceutical company
- Alexion Pharma UK Ltd
- Submission type
- Non submission
- Not recommended
- Date advice published
- 08 November 2021